NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients.

Détails

ID Serval
serval:BIB_0D93650C7F77
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients.
Périodique
European Journal of Immunology
Auteur(s)
Harari A., Rozot V., Cavassini M., Enders F.B., Vigano S., Tapia G., Castro E., Burnet S., Lange J., Moog C., Garin D., Costagliola D., Autran B., Pantaleo G., Bart P.A.
ISSN
1521-4141 (Electronic)
ISSN-L
0014-2980
Statut éditorial
Publié
Date de publication
2012
Volume
42
Numéro
11
Pages
3038-3048
Langue
anglais
Notes
Publication types: Journal Article WOS Document Type: Article
Résumé
We report the results of the Theravac-01 phase I trial, which was conducted to evaluate the safety and immunogenicity of a poxvirus-based vector, NYVAC, expressing Gag, Pol, Nef, and Env from an HIV clade B isolate. NYVAC-B vaccine was injected intra-muscularly into ten HIV-infected patients successfully treated with antiretroviral therapy, twice on day 0 and again at week 4. Safety and immunogenicity were monitored for 48 weeks. HIV-specific T-cell responses following immunization were quantitatively analyzed using an IFN-γ ELISPOT assay and qualitatively characterized for their functional profile (including multiple cytokines secretion plus cytotoxic and proliferation capacity) by polychromatic flow cytometry. Our results indicate that the NYVAC-B vaccine is safe and highly immunogenic, as indicated by increased HIV-specific T-cell responses in virtually all vaccinees. Interestingly, both an expansion of preexisting T-cell responses, and the appearance of newly detected HIV-specific CD4(+) and CD8(+) T-cell responses were observed. Furthermore, immunization mostly induced an increase in Gag-specific T-cell responses. In conclusion, NYVAC-B immunization induces broad, vigorous, and polyfunctional HIV-specific T-cell responses, suggesting that poxvirus-based vaccine regimens may be instrumental in the therapeutic HIV vaccine field.
Pubmed
Web of science
Open Access
Oui
Création de la notice
13/12/2012 19:46
Dernière modification de la notice
08/05/2019 14:23
Données d'usage